Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Joshua AM, et al. Among authors: beer tm. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26. Eur J Cancer. 2022. PMID: 35643841 Free PMC article.
The medical management of prostate cancer: a multidisciplinary team approach.
Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. Sternberg CN, et al. Among authors: beer tm. BJU Int. 2007 Jan;99(1):22-7. doi: 10.1111/j.1464-410X.2006.06477.x. Epub 2006 Sep 6. BJU Int. 2007. PMID: 16956362 Review. No abstract available.
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI; American Society of Clinical Oncology. Basch EM, et al. Among authors: beer tm. J Clin Oncol. 2007 Nov 20;25(33):5313-8. doi: 10.1200/JCO.2007.13.4536. Epub 2007 Oct 9. J Clin Oncol. 2007. PMID: 17925542 Review.
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Beer TM, et al. Cancer. 2008 Jan 15;112(2):326-30. doi: 10.1002/cncr.23163. Cancer. 2008. PMID: 17960793 Free article. Clinical Trial.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Scher HI, et al. Among authors: beer tm. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. J Clin Oncol. 2008. PMID: 18309951 Free PMC article.
300 results